While data on B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy in RR AL amyloidosis is minimal, understanding this emerging treatment avenue is increasingly important. This evidence concerns the gene TNFRSF17 and AL amyloidosis.